A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections

← catalyst calendar

NCT06056297 · readout ≤ 407 d

Sponsored by X4 Pharmaceuticals (industry) · XFOR — their whole pipeline →.

Phase

Phase 3

Status

Recruiting

Study type

Interventional

Design

Randomized · Quadruple · Treatment

Enrollment

176estimated

Sites

114

Countries

Argentina, Australia, Belgium +22

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2024-06-06

actual

When the study began enrolling

Primary completion

Sep 2027

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Nov 2027

estimated

The whole study's end, after follow-up

First posted

2023-09-28

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-08-06

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Neutropenia

Interventions

Drug: Mavorixafor — also filed as X4P-001
Drug: Placebo

Primary outcomes

what the primary-completion date above is the date OF

Co-primary Endpoint: Annualized Infection Rate Based on Infections Adjudicated by Blinded Infection Adjudication Committee (BIAC) During the Treatment Period

measured Up to 52 Weeks

Co-primary Endpoint: Number of Participants Meeting the Definition of a Positive Absolute Neutrophil Count (ANC) Response

measured Up to 52 weeks

Permalink · XFOR's whole pipeline · Catalyst calendar · Every registered study · What changed